Evidence map›Paper›PMID 24852934›Full record

ReviewThe American journal of medicine2014

Pneumococcal vaccine and patients with pulmonary diseases.

Mehdi Mirsaeidi, Golnaz Ebrahimi, Mary Beth Allen, Stefano Aliberti

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The American journal of medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Infectious Complications of Pulmonary Sarcoidosis.Journal of clinical medicine · 2024
    Review
  4. Environmental Causes of Idiopathic Pulmonary Fibrosis.International journal of molecular sciences · 2023
    Review
  5. Review
  6. Article
  7. Observational
  8. Review
  9. Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019
    Article
  10. Observational
  11. Article
  12. Review
  13. Pneumococcal Vaccination Among Adults With Work-related Asthma.American journal of preventive medicine · 2017
    Article
  14. Observational
  15. Observational
  16. Observational
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Mehdi MirsaeidiUniversity of Illinois at Chicago, Division of Pulmonary and Critical Care, Chicago. Electronic address: mmirsae@uic.edu.
Golnaz EbrahimiUniversity of Illinois at Chicago, Division of Pulmonary and Critical Care, Chicago.
Mary Beth AllenUniversity of Louisville, Department of Health, Louisville, Ky.
Stefano AlibertiUniversity of Milan Bicocca, Department of Health Science, Clinica Pneumologica, AO San Gerardo, Monza, Italy.
University of Illinois Chicago · USUniversity of Louisville · USUniversity of Milano-Bicocca · IT

Funding

Pulmonary and Critical Care Post-Doctoral Research Training ProgramT32HL082547 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI FINN, PATRICIA W · 2007 to 2017
$2.7M
NHLBI NIH HHS 5 T32 HL 82547-7NHLBI NIH HHS T32 HL082547
6 · The paper itself

Abstract

Chronic pulmonary diseases are chronic diseases that affect the airways and lung parenchyma. Examples of common chronic pulmonary diseases include asthma, bronchiectasis, chronic obstructive lung disease, lung fibrosis, sarcoidosis, pulmonary hypertension, and cor pulmonale. Pulmonary infection is considered a significant cause of mortality in patients with chronic pulmonary diseases. Streptococcus pneumoniae is the leading isolated bacteria from adult patients with community-acquired pneumonia, the most common pulmonary infection. Vaccination against S. pneumoniae can reduce the risk of mortality, especially from more serious infections in both immunocompetent and immunocompromised patients. Patients with chronic pulmonary diseases who take steroids or immunomodulating therapy (eg, methotrexate, anti-tumor necrosis factor inhibitors), or who have concurrent sickle cell disease or other hemoglobinopathies, primary immunodeficiency disorders, human immunodeficiency virus infection/acquired immunodeficiency syndrome, nephrotic syndrome, and hematologic or solid malignancies should be vaccinated with both 13-valent pneumococcal conjugate vaccine and the pneumococcal polysaccharide vaccine 23-valent.

Indexed as

Pneumococcal VaccinesChronic DiseaseHumansLung DiseasesPneumonia, PneumococcalRisk FactorsVaccination13-valent pneumococcal vaccine23-valent pneumococcal capsular polysaccharide vaccinePneumococcal VaccinesInvasive pneumococcal diseasePneumococcalPneumoniaPulmonaryStreptococcus pneumoniaeVaccination

Identifiers

PMID24852934
PMCPMC4161643
OpenAlexW2029177335

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.